Press coverage about Second Sight Medical Products (NASDAQ:EYES) has been trending somewhat positive on Friday, Accern Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Second Sight Medical Products earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned news articles about the medical device company an impact score of 45.7789518236265 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

EYES has been the subject of a number of recent analyst reports. ValuEngine raised shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Zacks Investment Research raised shares of Second Sight Medical Products from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research report on Thursday, May 17th. Finally, HC Wainwright set a $5.00 target price on shares of Second Sight Medical Products and gave the company a “buy” rating in a research report on Tuesday, May 15th.

Shares of Second Sight Medical Products stock traded up $0.01 on Friday, reaching $1.54. 116,800 shares of the company traded hands, compared to its average volume of 419,796. Second Sight Medical Products has a 52 week low of $0.96 and a 52 week high of $2.58. The company has a market capitalization of $107.99 million, a P/E ratio of -2.61 and a beta of 3.08.

Second Sight Medical Products (NASDAQ:EYES) last released its earnings results on Tuesday, August 7th. The medical device company reported ($0.12) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02. Second Sight Medical Products had a negative net margin of 418.82% and a negative return on equity of 432.45%. The firm had revenue of $1.91 million during the quarter, compared to the consensus estimate of $2.21 million. research analysts expect that Second Sight Medical Products will post -0.58 earnings per share for the current fiscal year.

In related news, Director Gregg Williams bought 25,355 shares of Second Sight Medical Products stock in a transaction dated Friday, June 1st. The stock was purchased at an average cost of $1.99 per share, with a total value of $50,456.45. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Edward David Randolph sold 16,023 shares of the stock in a transaction that occurred on Friday, June 1st. The shares were sold at an average price of $1.96, for a total transaction of $31,405.08. Following the transaction, the vice president now directly owns 16,045 shares of the company’s stock, valued at $31,448.20. The disclosure for this sale can be found here. Over the last three months, insiders have bought 3,579,165 shares of company stock valued at $5,629,244 and have sold 27,213 shares valued at $54,164. 48.30% of the stock is owned by corporate insiders.

About Second Sight Medical Products

Second Sight Medical Products, Inc, together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa.

Featured Story: Diversification Important in Investing

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.